In summary, our study shows that FOXM1 is a potential therapeutic target in SCLC and its inhibition using small molecule inhibitors (FDI-6 or NB-73) elicits effective antitumor response in multiple SCLC cell lines, xenograft, and spontaneous tumor models. Here, FOXM1 is linked to small cell lung carcinoma.